Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026...

Related Keywords

Australia ,Mike Andriole ,Marcd Kozin ,Patrick Machado ,Oncology Consortium ,Therapeutic Goods Administration ,National Institutes Of Health ,Company To Advance Dordaviprone ,Exchange Commission ,Company Board Of Directors ,Reiterates Expectations ,Interim Overall Survival ,Preliminary Phase ,Data Expected This Summer ,Advance Dordaviprone ,Conference Call ,Chief Executive Officer ,National Institutes ,Pacific Pediatric Neuro Oncology Consortium ,Chimerix Board ,Private Securities Litigation Reform Act ,Provisional Determination ,Months Ended March ,